US FDA plans September panel meeting for Arena's lorcaserin
This article was originally published in Scrip
Executive Summary
The US FDA has scheduled a panel meeting for Arena Pharmaceuticals' experimental anti-obesity drug, lorcaserin. The endocrinologic and metabolic drugs advisory committee is due to meet to discuss the therapy on 16 September.